ArticleFrontiers in pharmacology2024
A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system.
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 46 citations in OpenAlex.
- Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Hematological toxicities and thrombosis risk associated with immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2024.Cancer immunology, immunotherapy : CII · 2026Article
- Real-world safety of satralizumab in neuromyelitis optica spectrum disorder: a FAERS-based risk stratification study.Journal of neurology · 2026Article
- Disproportionality analysis and "perpetrator" or "accomplice" review of Baloxavir marboxil in public FAERS database.BMC infectious diseases · 2026Article
- Gastrointestinal safety of oral erythromycin, clarithromycin, and azithromycin in pediatric patients: a FAERS pharmacovigilance study.Pediatric research · 2026Article
- Spectrum and signals of medication-associated cognitive disorder: a comprehensive disproportionality analysis with cross-database validation.Frontiers in pharmacology · 2026Article
- Adverse event profile of fondaparinux sodium: a disproportionality analysis based on FAERS, JADER, and VigiAccess databases.Frontiers in medicine · 2026Article
- A FAERS database study on visual impairment adverse events associated with three long-acting insulin analogues.Frontiers in endocrinology · 2026Article
- Sex-specific adverse event profiles of PDE4 inhibitors: a comparative big-data pharmacovigilance study of apremilast, crisaborole, and roflumilast in FAERS (2004-2025).Frontiers in pharmacology · 2026Article
- Observational
- Real-world safety profile of etelcalcetide in dialysis-related secondary hyperparathyroidism: a pharmacovigilance analysis of FAERS data.Renal failure · 2025Article
- Drug-induced immune-mediated uveitis: a real-world pharmacovigilance analysis using FAERS and JADER databases.BMJ open ophthalmology · 2025Article
- A Real-World Pharmacovigilance Study of Fruquintinib Based on the FDA Adverse Event Reporting System (FAERS) Database.Cancer medicine · 2025Article
- Post-market safety profile and suicide/self-injury risk signals of dextromethorphan/bupropion: a real-world pharmacovigilance study.European journal of clinical pharmacology · 2025Article
- Drug-Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database.Scientific reports · 2025Article
- A disproportionality analysis of FDA adverse event reporting system (FAERS) events for methimazole and propylthiouracil.PloS one · 2025Article
- Remimazolam's clinical application and safety: A signal detection analysis based on FAERS data and literature support.PloS one · 2025Article
- A real-world disproportionality analysis of ripretinib data mining of the public version of FDA adverse event reporting system.Frontiers in pharmacology · 2025Article
- Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.